MCID: KDN018
MIFTS: 75

Kidney Disease

Categories: Blood diseases, Genetic diseases, Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Kidney Disease

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 11 28 5 14 38 16 75
Renal Failure 75 53 5 38 31
Kidney Failure 41 16 71 33
Kidney Diseases 41 43 71
Abnormality of the Kidney 28 5
Nephropathy 11 75
Impaired Renal Function Disease 11
Renal Failure Adverse Event 71
Abnormal Renal Function 71
Kidney Dysfunction 53
Renal Anomaly 53
Renal Disease 53
Nephropathies 14

Classifications:



External Ids:

Disease Ontology 11 DOID:557
MeSH 43 D007674
NCIt 49 C3149
SNOMED-CT 68 266612003
ICD10 31 N08 N17-N19 N19
UMLS 71 C0022658 C0035078 C0151746 more

Summaries for Kidney Disease

MedlinePlus: 41 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Kidney Disease, also known as renal failure, is related to chronic kidney disease and autosomal dominant polycystic kidney disease, and has symptoms including polyuria An important gene associated with Kidney Disease is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are Epithelial to mesenchymal transition in colorectal cancer and Bardet-Biedl syndrome. The drugs Nicotinamide and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone marrow, and related phenotypes are renal/urinary system and growth/size/body region

Disease Ontology: 11 A urinary system disease that is located in the kidney.

Wikipedia 75 Nephropathy: Kidney disease, or renal disease, technically referred to as nephropathy, is damage to or disease of a... more...

Renal failure: Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys can... more...

Related Diseases for Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3607)
# Related Disease Score Top Affiliating Genes
1 chronic kidney disease 34.5 WT1 UMOD REN PKD2 PKD1 NPHS1
2 autosomal dominant polycystic kidney disease 34.2 UMOD TSC1 REN PKHD1 PKD2L1 PKD2
3 polycystic kidney disease 34.2 UMOD TSC1 REN PKHD1 PKD2L1 PKD2
4 polycystic kidney disease 1 with or without polycystic liver disease 34.0 TSC1 REN PKHD1 PKD2L1 PKD2 PKD1
5 cystic kidney disease 33.9 UMOD TSC1 REN PKHD1 PKD2L1 PKD2
6 polycystic kidney disease 4 with or without polycystic liver disease 33.8 UMOD PKHD1 PKD2 PKD1 NPHP4 CEP290
7 polycystic kidney disease 2 with or without polycystic liver disease 33.8 PKHD1 PKD2L1 PKD2 PKD1
8 end stage renal disease 33.5 PKD2 PKD1 NPHP4 INF2 COL4A5 COL4A4
9 polycystic kidney disease 3 with or without polycystic liver disease 33.5 PKD2 PKD1
10 nephronophthisis 33.3 UMOD PKHD1 PKD2 PKD1 NPHP4 CEP290
11 polycystic kidney disease 4 33.1 REN PKHD1
12 alport syndrome 33.0 WT1 UMOD REN NPHS1 INF2 COL4A5
13 microvascular complications of diabetes 3 33.0 REN NPHS1 ALB
14 polycystic liver disease 32.9 UMOD PKHD1 PKD2L1 PKD2 PKD1 ALB
15 acute kidney failure 32.9 UMOD REN CST3 ALB
16 glomerulonephritis 32.9 REN NPHS1 COL4A5 COL4A4 COL4A3 ALB
17 hypertension, essential 32.9 UMOD REN PKD2 PKD1 NPHS1 MIR141
18 caroli disease 32.8 PKHD1 PKD2 PKD1
19 autosomal dominant alport syndrome 32.6 COL4A5 COL4A4 COL4A3
20 autosomal recessive alport syndrome 32.6 NPHS1 INF2 COL4A5 COL4A4 COL4A3
21 congenital hepatic fibrosis 32.6 PKHD1 PKD2 PKD1
22 polycystic liver disease 1 with or without kidney cysts 32.5 TSC1 PKHD1 PKD2 PKD1 NPHP4
23 iga glomerulonephritis 32.5 REN NPHS1 ALB
24 renal fibrosis 32.5 REN NPHP4 ALB
25 ureteral disease 32.4 UMOD REN NPHS1 ALB
26 joubert syndrome 1 32.4 PKHD1 PKD2 PKD1 NPHP4 CEP290
27 anuria 32.4 REN CST3 ALB
28 nail-patella syndrome 32.3 NPHS1 INF2 COL4A5 COL4A4 COL4A3
29 goodpasture syndrome 32.3 NPHS1 COL4A5 COL4A4 COL4A3 ALB
30 hyperuricemia 32.3 UMOD REN ALB
31 urinary tract infection 32.3 UMOD REN CST3 ALB
32 lipoid nephrosis 32.3 WT1 NPHS1 INF2 ALB
33 obstructive nephropathy 32.2 REN MIR200A ALB
34 nephrotic syndrome 32.2 WT1 REN NPHS1 INF2 COL4A5 COL4A4
35 focal segmental glomerulosclerosis 32.2 WT1 REN NPHS1 INF2 COL4A5 COL4A4
36 denys-drash syndrome 32.2 WT1 NPHS1 INF2
37 renal dysplasia, cystic 32.2 UMOD PKHD1 PKD1 CEP290
38 familial nephrotic syndrome 32.1 WT1 NPHS1 INF2 COL4A5 COL4A3
39 gout 32.0 UMOD PKD2 ALB
40 interstitial nephritis 32.0 UMOD REN CST3 ALB
41 cakut 32.0 WT1 UMOD REN PKHD1 NPHS1 NPHP4
42 nephronophthisis 19 31.9 PKHD1 NPHP4 CEP290
43 frasier syndrome 31.9 WT1 NPHS1 INF2
44 arima syndrome 31.9 NPHP4 CEP290
45 urinary tract obstruction 31.9 UMOD REN NPHS1 CST3 ALB
46 peripheral artery disease 31.9 REN CST3 ALB
47 multicystic dysplastic kidney 31.9 REN PKD2 PKD1
48 portal hypertension 31.8 REN PKHD1 ALB
49 vesicoureteral reflux 31.7 UMOD REN PKHD1 CST3 ALB
50 acute kidney tubular necrosis 31.7 UMOD REN CST3 ALB

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease, Familial, 1 Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Encephalopathy
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Heart Disease
Hydronephrosis Hypertension, Essential
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Third-Degree Atrioventricular Block Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease

Symptoms & Phenotypes for Kidney Disease

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 10.17 ALB CEP290 COL4A3 COL4A4 COL4A5 NPHP4
2 growth/size/body region MP:0005378 10.07 CEP290 COL4A3 COL4A4 COL4A5 INF2 NEAT1
3 cellular MP:0005384 9.93 ALB CEP290 COL4A3 CST3 NEAT1 NPHP4
4 cardiovascular system MP:0005385 9.8 ALB CEP290 COL4A3 COL4A5 CST3 INF2
5 mortality/aging MP:0010768 9.47 ALB CEP290 COL4A3 COL4A4 COL4A5 CST3

Drugs & Therapeutics for Kidney Disease

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 907)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
2
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
3
Triamterene Approved Phase 4 396-01-0 5546
4
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
5
Capsaicin Approved Phase 4 404-86-4 1548943
6
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
7
Digoxin Approved Phase 4 20830-75-5 3062 2724385 30322
8
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
9
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
10
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
11
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
12
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2
13
Captopril Approved Phase 4 62571-86-2 44093
14
Cinacalcet Approved Phase 4 226256-56-0 156419
15
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
16
Carbamide peroxide Approved Phase 4 124-43-6
17
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
18
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
19
Amlodipine Approved Phase 4 88150-42-9 2162
20
Ezetimibe Approved Phase 4 163222-33-1 150311
21
Reviparin Approved, Investigational Phase 4 9041-08-1
22
Hydroxyurea Approved Phase 4 127-07-1 3657
23
Hydralazine Approved Phase 4 86-54-4 3637
24
Rilonacept Approved, Investigational Phase 4 501081-76-1
25
Candesartan cilexetil Approved Phase 4 145040-37-5
26
Telavancin Approved Phase 4 372151-71-8 21014972 3081362
27
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
28
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
29
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Aminophylline Approved Phase 4 317-34-0 9433
32
Regadenoson Approved, Investigational Phase 4 313348-27-5 22451303 219024
33
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
34
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
35
Pitavastatin Approved Phase 4 147511-69-1 5282452
36
Insulin glulisine Approved Phase 4 207748-29-6
37
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
38
Atenolol Approved Phase 4 29122-68-7 2249
39
Doxazosin Approved Phase 4 74191-85-8 3157
40
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
41
Manidipine Approved, Investigational Phase 4 89226-50-6 4008
42
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
43
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
44
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
45
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
46
Pamidronic acid Approved Phase 4 40391-99-9 4674
47
Zoledronic acid Approved Phase 4 118072-93-8 68740
48
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
49
Vancomycin Approved Phase 4 1404-90-6 14969
50
Asunaprevir Approved, Investigational, Withdrawn Phase 4 630420-16-5 23595629

Interventional clinical trials:

(show top 50) (show all 5642)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis:A Multicenter Randomized Controlled Clinical Trial Unknown status NCT04349683 Phase 4 Jinshuibao;Placebo
2 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
3 Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD) Unknown status NCT04215445 Phase 4 Empagliflozin 25 MG
4 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
5 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
6 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
7 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
8 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
9 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
10 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
11 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
12 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
13 Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz) Unknown status NCT02648126 Phase 4
14 Lipid-lowering Regimes Improve Oxidative Stress, Tryptophan Degradation in Hypercholesterolemia Chronic Kidney Disease Patients Unknown status NCT03543774 Phase 4 Simvastatin 40mg;Ezetimibe/simvastatin 10/20 mg/day;Ezetimibe/simvastatin 10/40 mg/day
15 A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease Unknown status NCT02522650 Phase 4 Amiloride;Triamterene
16 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
17 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
18 Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Unknown status NCT03596957 Phase 4 Tolvaptan
19 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
20 Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease Unknown status NCT02364648 Phase 4
21 Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) Unknown status NCT03195023 Phase 4 Lisinopril;Amlodipine
22 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
23 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
24 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
25 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril
26 Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria Unknown status NCT03550859 Phase 4 Telmisartan/Rosuvastatin 40/10mg;Telmisartan 40mg
27 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
28 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
29 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
30 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
31 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
32 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
33 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
34 Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial. Unknown status NCT01481688 Phase 4
35 Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia Unknown status NCT04659525 Phase 4 Evolocumab;Ezetimibe;Placebo
36 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
37 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
38 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
39 Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia Unknown status NCT04397653 Phase 4 Evolocumab;Placebo;Ezetimibe
40 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
41 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
42 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
43 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
44 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
45 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
46 Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study Unknown status NCT03470961 Phase 4 Anti-Tlymphocyte Globulins;Anti-Thymocyte Globulins
47 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
48 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
49 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
50 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Albumin Human, USP
ALBUMIN,HUMAN INJ
Dopamine
Dopamine Hydrochloride

Cochrane evidence based reviews: kidney diseases

Genetic Tests for Kidney Disease

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Kidney 28
2 Kidney Disease 28

Anatomical Context for Kidney Disease

Organs/tissues related to Kidney Disease:

FMA: Kidney
MalaCards : Kidney, Heart, Bone Marrow, Endothelial, Bone, Liver, Skeletal Muscle

Publications for Kidney Disease

Articles related to Kidney Disease:

(show top 50) (show all 62532)
# Title Authors PMID Year
1
Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. 41
36451454 2022
2
Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries|. 41
36044940 2022
3
Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial. 41
36206005 2022
4
The impact of logo-therapy on disease acceptance and self-awareness of patients undergoing hemodialysis; a pre-test-post-test research. 41
36316706 2022
5
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial. 41
36127497 2022
6
Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial. 41
36036936 2022
7
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. 46
20952520 2011
8
Tumor necrosis factor (TNF-alpha) and C-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. 53 62
20499416 2010
9
An aid to the diagnosis of genetic disorders underlying adult-onset renal failure: a literature review. 53 62
20497759 2010
10
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. 53 62
20061322 2010
11
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. 53 62
20200094 2010
12
An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. 53 62
20336053 2010
13
Evidence for a role of uromodulin in chronic kidney disease progression. 53 62
20075439 2010
14
Increment and impairment of adiponectin in renal failure. 53 62
20035033 2010
15
Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. 53 62
20116156 2010
16
Performance evaluation of a particle-enhanced turbidimetric cystatin C assay using the Abbott Aeroset analyser and assessment of cystatin C-based equations for estimating glomerular filtration rate in chronic kidney disease. 53 62
20037185 2010
17
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. 53 62
20224047 2010
18
Terlipressin therapy for renal failure in cirrhosis. 53 62
19952764 2010
19
The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. 53 62
20133489 2010
20
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. 53 62
20470305 2010
21
Aldose reductase inhibitors and diabetic kidney disease. 53 62
20336588 2010
22
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. 53 62
20157196 2010
23
Molecular diagnostics for autosomal dominant polycystic kidney disease. 53 62
20177400 2010
24
Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. 53 62
20486990 2010
25
Predicting potential survival benefit of renal transplantation in patients with chronic kidney disease. 53 62
20351122 2010
26
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 53 62
20150538 2010
27
Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. 53 62
19303331 2010
28
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. 53 62
20016471 2010
29
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. 53 62
20133492 2010
30
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. 53 62
19948877 2010
31
Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. 53 62
20368098 2010
32
Antagonists of bone morphogenetic proteins in kidney disease. 53 62
20178045 2010
33
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study. 53 62
20050832 2010
34
FGF23-parathyroid interaction: implications in chronic kidney disease. 53 62
20010546 2010
35
Genetic variation at selected SNPs in the leptin gene and association of alleles with markers of kidney disease in a Xhosa population of South Africa. 53 62
20140086 2010
36
PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. 53 62
19914852 2010
37
Alterations of retinol-binding protein 4 species in patients with different stages of chronic kidney disease and their relation to lipid parameters. 53 62
20097162 2010
38
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 53 62
19929273 2010
39
Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. 53 62
19955654 2010
40
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. 53 62
19955044 2010
41
Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. 53 62
19887788 2010
42
Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. 53 62
20091482 2010
43
The role of vitamin D receptor activation in chronic kidney disease. 53 62
20411052 2010
44
Susceptibility genes in common complex kidney disease. 53 62
19838113 2010
45
Elevated brain natriuretic peptide is associated with abnormal heart geometry in children with chronic kidney disease. 53 62
20234137 2010
46
Influence of chronic renal failure on acid secretion in isolated gastric mucosal cells from human biopsies. 53 62
20380354 2010
47
Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure. 53 62
19965530 2010
48
Role of 11beta-hydroxysteroid dehydrogenase 2 renal activity in potassium homeostasis in rats with chronic renal failure. 53 62
20027486 2010
49
Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. 53 62
20091490 2010
50
Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease. 53 62
20040346 2010

Variations for Kidney Disease

ClinVar genetic disease variations for Kidney Disease:

5 (show top 50) (show all 335)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CEP290 NM_025114.4(CEP290):c.3104-2A>G SNV Pathogenic
374210 rs773386777 GRCh37: 12:88487754-88487754
GRCh38: 12:88093977-88093977
2 PKHD1 NM_138694.4(PKHD1):c.370C>T (p.Arg124Ter) SNV Pathogenic
167499 rs727504096 GRCh37: 6:51944718-51944718
GRCh38: 6:52079920-52079920
3 overlap with 51 genes GRCh37/hg19 1p32.3-32.2(chr1:51941877-56688514) CN LOSS Pathogenic
1047872 GRCh37: 1:51941877-56688514
GRCh38:
4 WT1 NM_024426.6(WT1):c.1399C>T (p.Arg467Trp) SNV Pathogenic
3487 rs121907900 GRCh37: 11:32413566-32413566
GRCh38: 11:32392020-32392020
5 NPHP4 NM_015102.5(NPHP4):c.3644+1G>A SNV Pathogenic
867163 rs756111113 GRCh37: 1:5926432-5926432
GRCh38: 1:5866372-5866372
6 INF2 NM_022489.4(INF2):c.653G>A (p.Arg218Gln) SNV Pathogenic
1051 rs267607183 GRCh37: 14:105169777-105169777
GRCh38: 14:104703440-104703440
7 TSC1 NM_000368.5(TSC1):c.989dup (p.Ser331fs) DUP Pathogenic
49135 rs118203478 GRCh37: 9:135786879-135786880
GRCh38: 9:132911492-132911493
8 PKHD1 NM_138694.4(PKHD1):c.107C>T (p.Thr36Met) SNV Pathogenic
4108 rs137852944 GRCh37: 6:51947999-51947999
GRCh38: 6:52083201-52083201
9 CEP290 NM_025114.4(CEP290):c.6798G>A (p.Trp2266Ter) SNV Pathogenic
497937 rs760540562 GRCh37: 12:88452645-88452645
GRCh38: 12:88058868-88058868
10 CEP290 NM_025114.4(CEP290):c.5493del (p.Ala1832fs) DEL Pathogenic
56739 rs386834158 GRCh37: 12:88471567-88471567
GRCh38: 12:88077790-88077790
11 PKD1 NM_001009944.3(PKD1):c.3785A>G (p.His1262Arg) SNV Likely Pathogenic
374206 rs1057518976 GRCh37: 16:2161383-2161383
GRCh38: 16:2111382-2111382
12 NPHS1 NM_004646.4(NPHS1):c.1379G>A (p.Arg460Gln) SNV Likely Pathogenic
56438 rs386833880 GRCh37: 19:36339004-36339004
GRCh38: 19:35848102-35848102
13 WT1 NM_024426.6(WT1):c.1400G>A (p.Arg467Gln) SNV Likely Pathogenic
419332 rs121907903 GRCh37: 11:32413565-32413565
GRCh38: 11:32392019-32392019
14 NPHS1 NM_004646.4(NPHS1):c.3549C>A (p.Tyr1183Ter) SNV Likely Pathogenic
552390 rs767887213 GRCh37: 19:36321791-36321791
GRCh38: 19:35830889-35830889
15 MEFV NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg) SNV Likely Pathogenic
2547 rs104895094 GRCh37: 16:3293403-3293403
GRCh38: 16:3243403-3243403
16 INF2 NM_022489.4(INF2):c.641G>A (p.Arg214His) SNV Likely Pathogenic
1053 rs267606879 GRCh37: 14:105169765-105169765
GRCh38: 14:104703428-104703428
17 LAMB2 NM_002292.4(LAMB2):c.2369C>G (p.Ser790Ter) SNV Likely Pathogenic
1712424 GRCh37: 3:49163299-49163299
GRCh38: 3:49125866-49125866
18 INF2 NM_022489.4(INF2):c.658G>A (p.Glu220Lys) SNV Likely Pathogenic
523533 rs530391015 GRCh37: 14:105169782-105169782
GRCh38: 14:104703445-104703445
19 MFF-DT, COL4A3 NM_000091.5(COL4A3):c.2656+1G>T SNV Likely Pathogenic
1712416 GRCh37: 2:228147249-228147249
GRCh38: 2:227282533-227282533
20 COL4A4 NM_000092.5(COL4A4):c.4440C>A (p.Cys1480Ter) SNV Likely Pathogenic
1712415 GRCh37: 2:227875111-227875111
GRCh38: 2:227010395-227010395
21 NPHP4 NM_015102.5(NPHP4):c.12G>A (p.Trp4Ter) SNV Likely Pathogenic
931168 rs780905861 GRCh37: 1:6046338-6046338
GRCh38: 1:5986278-5986278
22 PKD1 NM_001009944.3(PKD1):c.7904dup (p.Arg2636fs) DUP Likely Pathogenic
689540 rs1596536873 GRCh37: 16:2155434-2155435
GRCh38: 16:2105433-2105434
23 COQ8B NM_024876.4(COQ8B):c.1339dup (p.Glu447fs) DUP Likely Pathogenic
1708373 GRCh37: 19:41198235-41198236
GRCh38: 19:40692330-40692331
24 PKD1 NM_001009944.3(PKD1):c.3890_3891insCAC (p.Leu1297_Arg1298insThr) INSERT Likely Pathogenic
620077 rs1567202189 GRCh37: 16:2161277-2161278
GRCh38: 16:2111276-2111277
25 COL4A5 NM_033380.3(COL4A5):c.4706G>A (p.Arg1569Gln) SNV Likely Pathogenic
24757 rs281874743 GRCh37: X:107936155-107936155
GRCh38: X:108692925-108692925
26 COL4A5 NM_033380.3(COL4A5):c.4184dup (p.Pro1396fs) DUP Likely Pathogenic
1712353 GRCh37: X:107925085-107925086
GRCh38: X:108681855-108681856
27 INF2 NM_022489.4(INF2):c.451T>C (p.Cys151Arg) SNV Likely Pathogenic
1712412 GRCh37: 14:105169501-105169501
GRCh38: 14:104703164-104703164
28 NPHP1 NM_001128178.3(NPHP1):c.1045A>T (p.Ser349Cys) SNV Uncertain Significance
1712413 GRCh37: 2:110917742-110917742
GRCh38: 2:110160165-110160165
29 TRPC6 NM_004621.6(TRPC6):c.76A>T (p.Asn26Tyr) SNV Uncertain Significance
1712419 GRCh37: 11:101454159-101454159
GRCh38: 11:101583428-101583428
30 COL4A5 NM_033380.3(COL4A5):c.465G>A (p.Lys155_Gly156=) SNV Uncertain Significance
1712420 GRCh37: X:107815067-107815067
GRCh38: X:108571837-108571837
31 TRPC6 NM_004621.6(TRPC6):c.258C>T (p.Tyr86_Met87=) SNV Uncertain Significance
1712421 GRCh37: 11:101375442-101375442
GRCh38: 11:101504711-101504711
32 PLCE1 NM_016341.4(PLCE1):c.5625T>G (p.Ile1875Met) SNV Uncertain Significance
1712422 GRCh37: 10:96066186-96066186
GRCh38: 10:94306429-94306429
33 COQ2 NM_001358921.2(COQ2):c.951+8C>G SNV Uncertain Significance
1712423 GRCh37: 4:84188731-84188731
GRCh38: 4:83267578-83267578
34 CFH NM_000186.4(CFH):c.3493C>T (p.His1165Tyr) SNV Uncertain Significance
1712373 GRCh37: 1:196715129-196715129
GRCh38: 1:196745999-196745999
35 REN NM_000537.4(REN):c.492+6T>C SNV Uncertain Significance
1712374 GRCh37: 1:204129682-204129682
GRCh38: 1:204160554-204160554
36 CFHR3 NM_021023.6(CFHR3):c.355G>C (p.Gly119Arg) SNV Uncertain Significance
1712376 GRCh37: 1:196749028-196749028
GRCh38: 1:196779898-196779898
37 NPHS1 NM_004646.4(NPHS1):c.1108G>A (p.Val370Ile) SNV Uncertain Significance
1712410 GRCh37: 19:36339601-36339601
GRCh38: 19:35848699-35848699
38 MYH9 NM_002473.6(MYH9):c.2499+4C>T SNV Uncertain Significance
1712411 GRCh37: 22:36698610-36698610
GRCh38: 22:36302564-36302564
39 COQ2 NM_001358921.2(COQ2):c.739T>C (p.Tyr247His) SNV Uncertain Significance
1712354 GRCh37: 4:84191036-84191036
GRCh38: 4:83269883-83269883
40 COL4A4 NM_000092.5(COL4A4):c.2782_2799del (p.Cys928_Gly933del) DEL Uncertain Significance
1712355 GRCh37: 2:227919371-227919388
GRCh38: 2:227054655-227054672
41 DGKE NM_003647.3(DGKE):c.1347C>T (p.Ile449_Gly450=) SNV Uncertain Significance
1712363 GRCh37: 17:54939214-54939214
GRCh38: 17:56861853-56861853
42 C3 NM_000064.4(C3):c.3646+6G>A SNV Uncertain Significance
1712365 GRCh37: 19:6686751-6686751
GRCh38: 19:6686740-6686740
43 PLCE1 NM_016341.4(PLCE1):c.3595G>A (p.Gly1199Ser) SNV Uncertain Significance
1210225 GRCh37: 10:96018597-96018597
GRCh38: 10:94258840-94258840
44 LAMB2 NM_002292.4(LAMB2):c.4070C>T (p.Pro1357Leu) SNV Uncertain Significance
1521297 GRCh37: 3:49160719-49160719
GRCh38: 3:49123286-49123286
45 COL4A5 NM_033380.3(COL4A5):c.66G>A (p.Gln22=) SNV Uncertain Significance
1548560 GRCh37: X:107683421-107683421
GRCh38: X:108440191-108440191
46 CFH NM_000186.4(CFH):c.3045T>C (p.Thr1015=) SNV Uncertain Significance
1588570 GRCh37: 1:196711093-196711093
GRCh38: 1:196741963-196741963
47 MFF-DT, COL4A3 NM_000091.5(COL4A3):c.440C>T (p.Pro147Leu) SNV Uncertain Significance
1703962 GRCh37: 2:228111453-228111453
GRCh38: 2:227246737-227246737
48 NPHP3-ACAD11, NPHP3 NM_153240.5(NPHP3):c.2670T>G (p.Phe890Leu) SNV Uncertain Significance
1712346 GRCh37: 3:132409395-132409395
GRCh38: 3:132690551-132690551
49 PLCE1 NM_016341.4(PLCE1):c.826G>T (p.Val276Leu) SNV Uncertain Significance
1712347 GRCh37: 10:95791629-95791629
GRCh38: 10:94031872-94031872
50 TMEM67 NM_153704.6(TMEM67):c.2882C>A (p.Ser961Tyr) SNV Uncertain Significance
1712348 GRCh37: 8:94827650-94827650
GRCh38: 8:93815422-93815422

Copy number variations for Kidney Disease from CNVD:

6 (show all 21)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 22040 1 16450000 16950000 Duplication renal disease
2 37196 1 8700000 16000000 Deletion renal disease
3 76925 13 38159172 38359267 Copy number FREM2 renal disease
4 95843 15 81011700 83540700 Deletion renal disease
5 97939 16 14780000 16770000 Deletion renal disease
6 110304 17 31836750 33582750 Microdeletion renal disease
7 110305 17 31836750 33582750 Microdeletion CCL3L1 renal disease
8 110306 17 31836750 33582750 Microdeletion CCL4L1 renal disease
9 110307 17 31836750 33582750 Microdeletion HNF1B renal disease
10 110539 17 33120546 33179209 Copy number HNF1B renal disease
11 110540 17 33120546 33179209 Copy number HNF1B renal disease
12 110544 17 33120546 33179209 Deletion HNF1B renal disease
13 115163 17 55061600 55218400 Duplication renal disease
14 127179 19 28500000 63811651 Microdeletion renal disease
15 127247 19 30200000 37100000 Deletion renal disease
16 128207 19 40300000 43000000 Deletion renal disease
17 160230 22 11800000 24300000 Deletion renal disease
18 189838 4 79197747 79684447 Copy number FRAS1 renal disease
19 191442 5 1 12100000 Duplication renal disease
20 222025 7 148600000 158550000 Deletion renal disease
21 264973 X 71600000 71800000 Duplication renal disease

Expression for Kidney Disease

Search GEO for disease gene expression data for Kidney Disease.

Pathways for Kidney Disease

GO Terms for Kidney Disease

Cellular components related to Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 10.13 CST3 COL4A5 COL4A4 COL4A3 ALB
2 ciliary basal body GO:0036064 10.06 PKHD1 PKD2 NPHP4 CEP290
3 ciliary membrane GO:0060170 9.92 PKD1 PKD2 PKD2L1 UMOD
4 cilium GO:0005929 9.9 UMOD PKHD1 PKD2L1 PKD2 PKD1 NPHP4
5 non-motile cilium GO:0097730 9.88 PKD2L1 PKD2 NPHP4
6 polycystin complex GO:0002133 9.67 PKD2 PKD1
7 cation channel complex GO:0034703 9.65 PKD2L1 PKD2 PKD1
8 collagen type IV trimer GO:0005587 9.43 COL4A5 COL4A4 COL4A3
9 cell projection GO:0042995 9.32 UMOD TSC1 PKHD1 PKD2L1 PKD2 PKD1

Biological processes related to Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metanephric mesenchyme development GO:0072075 9.78 WT1 PKD2
2 cytoplasmic sequestering of transcription factor GO:0042994 9.76 PKD2 PKD1
3 mesonephric duct development GO:0072177 9.73 PKD2 PKD1
4 detection of mechanical stimulus GO:0050982 9.73 PKD1 PKD2 PKD2L1
5 metanephric S-shaped body morphogenesis GO:0072284 9.71 WT1 PKD2
6 mesonephric tubule development GO:0072164 9.67 PKD2 PKD1
7 metanephric ascending thin limb development GO:0072218 9.63 UMOD PKD2 PKD1
8 cell-cell signaling by wnt GO:0198738 9.62 PKD2 PKD1
9 glomerular basement membrane development GO:0032836 9.56 WT1 NPHS1 COL4A4 COL4A3
10 kidney development GO:0001822 9.47 WT1 UMOD TSC1 REN PKHD1 PKD2

Molecular functions related to Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 9.76 UMOD COL4A5 COL4A4 COL4A3
2 monoatomic cation channel activity GO:0005261 9.43 PKD2L1 PKD2 PKD1
3 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.1 COL4A5 COL4A4 COL4A3

Sources for Kidney Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....